ID

14657

Description

Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate.; ODM derived from: https://clinicaltrials.gov/show/NCT00195702

Lien

https://clinicaltrials.gov/show/NCT00195702

Mots-clés

  1. 25/04/2016 25/04/2016 -
Téléchargé le

25 avril 2016

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0

Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Rheumatoid Arthritis NCT00195702

Eligibility Rheumatoid Arthritis NCT00195702

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
age 18 or older and in good health (investigator discretion) with a recent stable medical history
Description

Age and health status

Type de données

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2]
C0018759
met american college of rheumatology (acr) criteria for diagnosis of active rheumatoid arthritis (ra) and had at both screening and baseline visits >=6 swollen joints and >=9 tender joints, despite a minimum of 3-months treatment with methotrexate (mtx). (distal interphalangeal joints [dips] were not to be included in joint count for inclusion. the screening and baseline visits could be 3 to 28 days apart for patients not previously receiving disease-modifying anti-rheumatic drugs [dmards] other than mtx or 4 to 6 weeks for patients requiring a dmard washout period.)
Description

American college of rheumatology criteria for diagnosis of active rheumatoid arthritis

Type de données

boolean

Alias
UMLS CUI [1]
C3273740
insufficient efficacy with mtx 12.5 to 25 mg per week (10 mg per week if mtx intolerant).
Description

MTX therapy

Type de données

boolean

Alias
UMLS CUI [1,1]
C0025677
UMLS CUI [1,2]
C0087111
if patient on a second-line treatment (dmard) other than mtx, he/she had to discontinue it for at least 28 days before the baseline visit (the washout period).
Description

Second-line treatment

Type de données

boolean

Alias
UMLS CUI [1]
C1710038
treatment with oral folic acid 1-3 mg/day or, if appropriate, up to 10 mg leucovorin per week.
Description

Oral folic acid and leucovorin

Type de données

boolean

Alias
UMLS CUI [1]
C3216389
UMLS CUI [2]
C0023413
both rheumatoid factor positivity and a c-reactive protein value >=1 mg/dl, or at least one joint erosion on x-ray.
Description

Rheumatoid factor, c-reactive protein and joint erosion on x-ray

Type de données

boolean

Alias
UMLS CUI [1]
C0035448
UMLS CUI [2]
C0006560
UMLS CUI [3]
C0003885
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
subject considered by the investigator, for any reason, to be an unsuitable candidate for the study.
Description

Exclusion criteria

Type de données

boolean

Alias
UMLS CUI [1]
C0680251
female subject who was pregnant or breast-feeding or considering becoming pregnant.
Description

Gynaecological status

Type de données

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
preceding treatment with any tumor necrosis factor (tnf) antagonist, including adalimumab.
Description

Adalimumab

Type de données

boolean

Alias
UMLS CUI [1]
C1122087
prior exposure to alkylating agents, such as chlorambucil or cyclophosphamide.
Description

Alkylating agents

Type de données

boolean

Alias
UMLS CUI [1]
C0002073
intra-articular, intramuscular, or intravenous administration of corticosteroids within 4 weeks prior to the screening visit.
Description

Corticosteroid therapy

Type de données

boolean

Alias
UMLS CUI [1]
C0149783
subject was wheelchair bound or bedridden.
Description

Wheelchair bound or bedridden

Type de données

boolean

Alias
UMLS CUI [1]
C0558195
UMLS CUI [2]
C0741453

Similar models

Eligibility Rheumatoid Arthritis NCT00195702

Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Age and health status
Item
age 18 or older and in good health (investigator discretion) with a recent stable medical history
boolean
C0001779 (UMLS CUI [1])
C0018759 (UMLS CUI [2])
American college of rheumatology criteria for diagnosis of active rheumatoid arthritis
Item
met american college of rheumatology (acr) criteria for diagnosis of active rheumatoid arthritis (ra) and had at both screening and baseline visits >=6 swollen joints and >=9 tender joints, despite a minimum of 3-months treatment with methotrexate (mtx). (distal interphalangeal joints [dips] were not to be included in joint count for inclusion. the screening and baseline visits could be 3 to 28 days apart for patients not previously receiving disease-modifying anti-rheumatic drugs [dmards] other than mtx or 4 to 6 weeks for patients requiring a dmard washout period.)
boolean
C3273740 (UMLS CUI [1])
MTX therapy
Item
insufficient efficacy with mtx 12.5 to 25 mg per week (10 mg per week if mtx intolerant).
boolean
C0025677 (UMLS CUI [1,1])
C0087111 (UMLS CUI [1,2])
Second-line treatment
Item
if patient on a second-line treatment (dmard) other than mtx, he/she had to discontinue it for at least 28 days before the baseline visit (the washout period).
boolean
C1710038 (UMLS CUI [1])
Oral folic acid and leucovorin
Item
treatment with oral folic acid 1-3 mg/day or, if appropriate, up to 10 mg leucovorin per week.
boolean
C3216389 (UMLS CUI [1])
C0023413 (UMLS CUI [2])
Rheumatoid factor, c-reactive protein and joint erosion on x-ray
Item
both rheumatoid factor positivity and a c-reactive protein value >=1 mg/dl, or at least one joint erosion on x-ray.
boolean
C0035448 (UMLS CUI [1])
C0006560 (UMLS CUI [2])
C0003885 (UMLS CUI [3])
Item Group
C0680251 (UMLS CUI)
Exclusion criteria
Item
subject considered by the investigator, for any reason, to be an unsuitable candidate for the study.
boolean
C0680251 (UMLS CUI [1])
Gynaecological status
Item
female subject who was pregnant or breast-feeding or considering becoming pregnant.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Adalimumab
Item
preceding treatment with any tumor necrosis factor (tnf) antagonist, including adalimumab.
boolean
C1122087 (UMLS CUI [1])
Alkylating agents
Item
prior exposure to alkylating agents, such as chlorambucil or cyclophosphamide.
boolean
C0002073 (UMLS CUI [1])
Corticosteroid therapy
Item
intra-articular, intramuscular, or intravenous administration of corticosteroids within 4 weeks prior to the screening visit.
boolean
C0149783 (UMLS CUI [1])
Wheelchair bound or bedridden
Item
subject was wheelchair bound or bedridden.
boolean
C0558195 (UMLS CUI [1])
C0741453 (UMLS CUI [2])

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial